Modification of topoisomerase genes copy number in newly diagnosed childhood acute lymphoblastic leukemia

Leukemia

Volumn 17, Issue 3, 2003, Pages 532-540

  Guerin E ^a,b   Entz Werle N ^a   Eyer, D ^a   Pencreac'h, E ^a   Schneider, A ^a   Falkenrodt, A ^a   Uettwiller, F ^a   Babin, A ^a   Voegeli, A C ^a,b   Lessard, M ^a   Gaub, M P ^a,b   Lutz, P ^a   Oudet, Pierre ^a,b  

^a HÔPITAL DE HAUTEPIERRE   (France)

^b INSERM   (France)

Author keywords

Childhood ALL; Risk assessment; Topoisomerase II alpha

Indexed keywords

ANTHRACYCLINE; DAUNORUBICIN; DNA; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIPODOPHYLLOTOXIN; ETOPOSIDE; GLUCOCORTICOID; IDARUBICIN; MICROSATELLITE DNA; RNA; TENIPOSIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLELE; ARTICLE; CANCER CLASSIFICATION; CANCER RISK; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MODIFICATION; FEMALE; GENE AMPLIFICATION; GENE LOCUS; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENOTYPE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; INFANT; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0345270452     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402774     Document Type: Article

References (52)

1. Pui CH. Acute lymphoblastic leukemia in children. Curr Opin Oncol 2000; 12: 3-12.
2. Silverman LB, Weinstein HJ. Treatment of childhood leukemia. Curr Opin Oncol 1997; 9: 26-33.
3. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 1998; 339: 605-615.
4. Wang JC. DNA topoisomerases. Annu Rev Biochem 1996; 65: 635-692.
5. Roca J. The mechanisms of DNA topoisomerases. Trends Biochem Sci 1995; 20: 156-160.
6. D'Arpa P, Machlin PS, Ratrie H 3rd, Rothfield NF, Cleveland DW, Earnshaw WC. cDNA cloning of human DNA topoisomerase I: catalytic activity of 67.7-kDa carboxyl-terminal fragment. Proc Natl Acad Sci USA 1988; 85: 2543-2547.
7. Hanai R, Caron PR, Wang JC. Human TOP3: a single-copy gene encoding DNA polymerase III. Proc Natl Acad Sci USA 1996; 93: 3653-3657.
8. Kawasaki K, Minoshima S, Nakato E, Shibuya K, Shintani A, Schmeits JL, Wang J, Shimizu N. One-megabase sequence analysis of the human immunoglobin lambda gene locus. Genome Res 1997; 7: 250-261.
9. Tsai-Pflugfelder M, Liu LF, Liu AA, Tewey KM, Whang-Peng J, Knutsen T, Huebner K, Croce CM, Wang JC. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci USA 1988; 85: 7177-7181.
10. Austin CA, Sng JH, Patel S, Fisher LM. Novel HeLa topoisomerase II is the II beta isoform: complete coding sequence and homology with other type II topoisomerases. Biochim Biophys Acta 1993; 1172: 283-291.
11. Heck MM, Hittelman WN, Earnshaw WC. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA 1988; 85: 1086-1090.
12. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ 1991; 2: 209-214.
13. Goswami PC, Roti Roti JL, Hunt CR. The cell cycle-coupled expression of topoisomerase IIα during S phase is regulated by mRNA stability and is disrupted by heat shock or ionizing radiation. Mol Cell Biol 1996; 16: 1500-1508.
14. Chen GL, Yang L, Rowe TC, Halligan BD, Tewey KM, Liu LF. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984; 259: 13 560-13 566.
15. Osheroff N. Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide. Biochemistry 1989; 28: 6157-6160.
16. Kaufmann SH, Gore SD, Miller CB, Jones RJ, Zwelling LA, Schneider E, Burke PJ, Karp JE. Topoisomerase II and the response to antileukemic therapy. Leuk Lymphoma 1998; 29: 217-237.
17. Kaufmann SH. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res 1989; 49: 5870-5878.
18. Walker PR, Smith C, Youdale T, Leblanc J, Whitfield JF, Sikorska M. Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes. Cancer Res 1991; 51: 1078-1085.
19. Bertrand R, Sarang M, Jenkin J, Kerrigan D, Pommier Y. Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression. Cancer Res 1991; 51: 6280-6285.
20. Danks MK, Schmidt CA, Cirtain MC, Suttle DP, Beck WT. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemia cells selected for resistance to VM-26. Biochemistry 1988; 27: 8861-8869.
21. Deffie AM, Batra JK, Goldenberg GJ. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res 1989; 49: 58-62.
22. Deffie AM, Bosman DJ, Goldenberg GJ. Evidence for a mutant allele of the gene for DNA topoisomerase II in adriamycin-resistant P388 murine leukemia cells. Cancer Res 1989; 49: 6879-6882.
23. Fernandes DJ, Danks MK, Beck WT. Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA. Biochemistry 1990; 29: 4235-4241.
24. Brown GA, McPherson JP, Gu L, Hedley DW, Toso R, Deuchars KL, Freedman MH, Goldenberg GJ. Relationship of DNA topoisomerase IIα and β expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines. Cancer Res 1995; 55: 78-82.
25. Towatari M, Adachi K, Marunouchi T, Saito H. Evidence for a critical role of DNA topoisomerase IIα in drug sensitivity revealed by inducible antisense RNA in a human leukaemia cell line. Br J Haematol 1998; 101: 548-551.
26. Bugg BY, Danks MK, Beck WT, Suttle DK. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc Natl Acad Sci USA 1991; 88: 7654-7658.
27. Hinds M, Deisseroth K, Mayes J, Altschuler E, Jansen R, Ledley FD, Zwelling LA. Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res 1991; 51: 4729-4731.
28. Lee MS, Wang JC, Beran M. Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of the human topoisomerase II. J Mol Biol 1992; 223: 837-843.
29. Vassetzky YS, Alghisi GC, Gasser SM. DNA topoisomerase II mutations and resistance to anti-tumor drugs. Bioessays 1995; 17: 767-774.
30. Asano T, An T, Mayes J, Zwelling LA, Kleinerman ES. Transfection of human topoisomerase IIα into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene. Biochem J 1996; 319: 307-313.
31. McPherson JP, Deffie AM, Jones NR, Brown GA, Deuchars KL, Goldenberg GJ. Selective sensitization of adriamycin-resistant P388 murine leukemia cells to antineoplastic agents following transfection with human DNA topoisomerase IIα. Anticancer Res 1997; 17: 4243-4252.
32. Dereuddre S, Delaporte C, Jacquemin-Sablon A. Role of topoisomerase IIβ in the resistance of 9-OH-ellipticine-resistant Chinese hamster fibiroblasts to topoisomerase II inhibitors. Cancer Res 1997; 57: 4301-4308.
33. Zhou Z, Zwelling LA, Kawakami Y, An T, Kobayashi K, Herzog C, Kleinerman ES. Adenovirus-mediated human topoisomerase IIα gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells. Cancer Res 1999; 59: 4618-4624.
34. Khélifa T, René B, Le Mée S, Lambert B, Saucier JM, Markovits J, Jacquemin-Sablon H, Jacquemin-Sablon A. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIα cDNA: selective restoration of the sensitivity to DNA religation inhibitors. Cancer Res 1999; 59: 4927-4936.
35. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000; 22: 263-302.
36. Felix CA. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta 1998; 1400: 233-255.
37. Pui CH, Relling MV. Topoisomerase II inhibitors-related acute myeloid leukemia. Br J Haematol 2000; 109: 13-23.
38. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, van't Veer MB. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995; 9: 1783-1786.
39. Vilmer E, Suciu S, Ferster A, Bertrand Y, Cave H, Thyss A, Benoit Y, Dastugue N, Fournier M, Souillet G, Manel AM, Robert A, Nelken B, Millot F, Lutz P, Rialland X, Mechinaud F, Boutard P, Behar C, Chantraine JM, Plouvier E, Laureys G, Brock P, Uytterbroeck A, Margueritte G, Plantaz D, Norton L, Francotte N, Gyselinck J, Waterkey C, Solbu G, Philipe N, Otten J. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia 2000; 14: 2257-2266.
40. Schneider A, Borgnat S, Lang H, Régine O, Lindner V, Kassem M, Saussine C, Oudet P, Jacqmin D, Gaub MP. Evaluation of microsatellite analysis in urine sediment for diagnosis of bladder cancer. Cancer Res 2000; 60: 4617-4622.
41. Schneider A, Rohr S, Kelly MD, Mitry R, Pignatelli M, Doré CJ, Gaub MP, Jaeck D, Meyer C, Oudet P, Habib NA. Microsatellite instability and allelic imbalance in primary and secondary colorectal cancer. Aust N Z J Surg 2000; 70: 587-592.
42. Campain JA, Slovak ML, Schoenlein PV, Popescu NC, Gottesman MM, Pastan I. Acquisition of multiple copies of a mutant topoisomerase IIα allele by chromosome 17 aneuploidy is associated with etoposide resistance in human melanoma cell lines. Somat Cell Mol Genet 1995; 21: 451-471.
43. Gekeler V, Frese G, Noller A, Handgretinger R, Wilisch A, Schmidt H, Muller CP, Dopfer R, Klingebiel T, Diddens H, Probst H, Niethammer D. Mdr1/9-glycoprotein, topoisomerase, and glutathione-S-transferase π gene expression in primary and relapsed state adult and childhood leukemias. Br J Cancer 1992; 66: 507-517.
44. Beck J, Handgretinger R, Dopfer R, Klingebiel T, Niethammer D, Gekeler V. Expression of mdr1, mrp, topoisomerase IIα/β, and cyclin A in primary or relapsed states of acute lymphoblastic leukemias. Br J Haematol 1995; 89: 356-363.
45. Klumper E, Giaccone G, Pieters R, Broekema G, van Ark-Otte J, van Wering ER, Kaspers GJL, Veerman AJP. Topoisomerase IIα gene expression in childhood acute lymphoblastic leukemia. Leukemia 1995; 9: 1653-1660.
46. Beck J, Niethammer D, Gekeler V. MDR1, MRP, topoisomerase IIα/β, and cyclin A gene expression in acute and chronic leukemias. Leukemia 1996; 10: S39-S45.
47. Stammler G, Sauerbrey A, Volm M. Determination of DNA topoisomerase II in newly diagnosed childhood acute lymphoblastic leukemia by immunocytochemistry and RT-PCR. Cancer Lett 1994; 4: 141-147.
48. Stammler G, Sauerbrey A, Volm M. Messenger RNA expression of resistance factors and their correlation to the proliferative activity in childhood acute lymphoblastic leukemia. Cancer Lett 1995; 89: 129-135.
49. Järvinen TAH, Tanner M, Bärlund M, Borg A, Isola J. Characterization of topoisomerase IIα gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 1999; 26: 142-150.
50. Järvinen TAH, Tanner M, Rantanen V, Bärlund M, Borg A, Grénman S, Isola J. Amplification and deletion of topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000; 156: 839-847.
51. McPherson JP, Goldenberg GJ. Induction of apoptosis by deregulated expression of DNA topoisomerase IIα. Cancer Res 1998; 58: 4519-4524.
52. Smets LA, Salomons G, van den Berg J. Glucocorticoid induced apoptosis in leukemia. Adv Exp Med Biol 1999; 457: 607-614.